SuperGen Nixes Phase III For Orathecin Combination Use In Pancreatic Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SuperGen is pulling the plug on plans for a randomized Phase III trial of its Orathecin combination therapy in first-line pancreatic cancer after a Phase II study fell short of a pre-specified threshold for median survival